Toggle navigation
Home
Search
Services
Blog
Contact
About
Rational Design of Neuropeptide Y Therapeutics
Salon, John A.
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States
Search 7 grants from John Salon
Search grants from Synaptic Pharmaceutical Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Surface-enhanced Raman Spectroscopy Immunoassay for Detection of Category A Patho
Oxygen Radicals and Cardiac Adaptations to Ischemia
Structure and Function of Heparin Cofactor II
Phosphate Metabolism in E. coli: Regulatory Genes
Curricular Modules: 3D and Immersive Visualization Tools forLearning
Recently added grants:
Molecular Transducers of Physical Activity and Health: NC Consortium Clinical Site
Molecular Transducers of Physical Activity Consortium - Colorado Clinical Center
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
Creating Hydrogel Tissue Mimics to Better Understand Congenital Heart Disease
Emergence of valence coding in the ventral striatum
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS031843-03
Application #
2269799
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (13))
Project Start
1994-09-01
Project End
1996-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652
Related projects
NIH 1995
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
NIH 1994
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
Comments
Be the first to comment on this grant